CELLINK to bring Livecyte high content live cell imager to a wider audience

Report this content

Today, CELLINK and Phasefocus announced a partnership to bring Livecyte, a high content live cell imager, to a wider market. Live cell imaging is essential to answering some of the most pressing questions in the life sciences, but conventional methods often involve labeling cells, a potentially harmful process that can alter research outcomes. Livecyte’s integration of the patented label-free Quantitative Phase Imaging technology with state-of-the-art automatic cell tracking algorithms enables users to automatically characterize growth, morphology and motility of large populations of cells in a 96-well plate assay format. Combining CELLINK’s already extensive product portfolio of bioprinters, liquid handlers and bioinks with Livecyte offers researchers a unique opportunity to improve workflow efficiencies in application areas such as drug discovery, regenerative medicine and cell-based assays.

“We have taken an important step to better serve our customer base by adding the groundbreaking Livecyte to our growing live cell imaging portfolio,” says Paul Berning, Head of Global Sales at CELLINK. “With the CELLCYTE X and Phasefocus’s high content live cell imager, our collaborators enjoy an uninterrupted workflow while pushing the boundaries of their work even further.”

Phasefocus CEO Martin Humphry adds, “We are very excited to be working with the talented team at CELLINK. Their complementary product portfolio and vision is a natural fit with Phasefocus. The partnership will help us reach a much wider customer base and bring the unique capabilities of Livecyte to a new audience.”

For more information, please contact:

Erik Gatenholm, CEO                                                                           Gusten Danielsson, CFO                             
Phone (Sweden): +46 73 267 00 00                                                       Phone (Sweden): +46 70 991 86 04      
Phone (US): +1 (650) 515 5566                                                             Phone (US): +1 (857) 332 2138
eg@cellink.com                                                                           Email: gd@cellink.com                               

This information was submitted for publication, through the agency of the contact persons set out above, on January 19, 2021, at 14:00 (CET).


CELLINK is the leading bio-convergence company and a global provider of technologies, products and services to create, understand and master biology. With a focus on the areas of bioprinting, biosciences and industrial solutions, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 700 publications. CELLINK is creating the future of medicine.

Visit www.cellink.com to learn more. CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.

About Phasefocus

Phasefocus is changing what is possible in live cell assays, helping scientists uncover subtle differences in cell behaviour across whole cell populations. The company’s products are based on a patented and award-winning computational imaging technology, called ptychography. From automated characterisation of live cell behaviour, to world-record-setting electron microscopy, Phasefocus is enabling advances in many diverse areas of scientific research.

Livecyte, Phasefocus's flagship product, delivers an unprecedented level of single-cell data from live cells. High-contrast label-free imaging, correlative fluorescence and powerful automated image analysis algorithms result in high-content time-lapse outputs from standard 96-well plate assays.
Find out more about Phasefocus at


Documents & Links